UBS Group
MAIA icon

UBS Group’s MAIA Biotechnology MAIA Stock Holding History

UBS Group’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$72.7K Buy
51,917
+49,747
+2,292% +$91.7K ﹤0.01% 7157
2025
Q4 		$3.32K Buy
+2,170
New +$2.83K ﹤0.01% 9051
2025
Q3 		– Sell
-2,120
Closed -$3.82K – 10675
2025
Q2 		$3.82K Buy
2,120
+1,820
+607% +$3.26K ﹤0.01% 9318
2025
Q1 		$459 Buy
+300
New +$555 ﹤0.01% 9772
2024
Q4 		– Sell
-16,685
Closed -$46.9K – 10213
2024
Q3 		$46.9K Buy
+16,685
New +$52K ﹤0.01% 6863
2024
Q1 		– Sell
-998
Closed -$1.17K – 9743
2023
Q4 		$1.17K Buy
998
+865
+650% +$1.4K ﹤0.01% 8387
2023
Q3 		$293 Buy
+133
New +$263 ﹤0.01% 8612
2023
Q2 		– Sell
-3,949
Closed -$13.7K – 9341
2023
Q1 		$13.7K Buy
3,949
+919
+30% +$3.78K ﹤0.01% 7385
2022
Q4 		$10.6K Sell
3,030
-1,558
-34% -$5.39K ﹤0.01% 8487
2022
Q3 		$15K Buy
+4,588
New +$19.4K ﹤0.01% 7810

Other funds holding MAIA

SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group's MAIA Position: Q1 2026 in Review

UBS Group increased its MAIA Biotechnology (MAIA) stake by 2,292% in Q1 2026, buying an estimated $91.7K and bringing the position to 51,917 shares worth $72.7K. The position accounts for ﹤0.01% of the portfolio, ranked #7157.

UBS Group first reported a position in MAIA in Q3 2022 and has held it in 10 quarters since. 33 funds tracked by Wall St. Rank hold MAIA as of Q1 2026.

  • UBS Group held 51,917 shares of MAIA Biotechnology worth $72.7K as of Q1 2026.
  • UBS Group bought 49,747 MAIA Biotechnology shares in Q1 2026, an estimated $91.7K.
  • MAIA Biotechnology made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7157 holding.
  • UBS Group first reported a position in MAIA Biotechnology in Q3 2022 and has held it in 10 quarters since.
  • 33 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.